Where is EBV acting in the causal pathway of MS? Early vs. Late? Central vs. Peripheral? #MSBlog #MSResearch
Epub: Simpson et al. EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. Acta Neurol Scand. 2014 Jun 3. doi: 10.1111/ane.12268.
BACKGROUND: Among the environmental factors associated with MS causation, some of the strongest associations are with EBV, and to a lesser extent human herpesvirus 6 (HHV6). Associations with clinical course are less conclusive, however.
METHODS: We evaluated serum anti-EBV-EA-R IgG and anti-HHV6 IgM, and EBV and HHV6 viral load (VL) for their associations with relapse, disability, and progression in disability in a prospective cohort of 198 participants with clinically definite MS.
RESULTS: Anti-EBV-EA-R IgG was detected in 81.8% of cases at study entry, and titres remained essentially unchanged during the study. Anti-HHV6 IgM was detected in only one participant, and EBV-VL (29%) and HHV6-VL (1.8%) were detected in a minority of samples, and where detected levels were low. Our previously demonstrated association between anti-HHV6 IgG and relapse hazard was not affected by adjustment for parameters of reactivation. We found no evidence that any of the viral markers were associated with disability or progression in disability. In relation to relapse, only EBV-VL was positively associated, although this was strongly influenced by a single individual.
CONCLUSION: Using a prospective cohort design, we found no convincing evidence that reactivation parameters of EBV or HHV6 were associated with subsequent MS relapse hazard or progression in disability, confirming previous findings, and indicating that herpes virus reactivation is not an important driver of relapse or disability in this established MS population.